Is PLX or PPBT more undervalued in 2026?

CirclFi compares Protalix BioTherapeutics, Inc. (PLX) and Purple Biotech Ltd. (PPBT) using 13 institutional-grade valuation models. PLX has a Quality of Company score of 7.6/10 while PPBT scores 3.6/10.

Which is a better buy — PLX or PPBT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLX and PPBT valuations compare?

PLX at $2.10 and PPBT at $2.81 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLX vs PPBT Valuation Comparison 2026 — Intrinsic Value Analysis

PLX

Biotechnology

Protalix BioTherapeutics, Inc.

Quality

7.6

out of 10

Value Trap

SAFE

Price

$2.10

Last close

Models

12/13

Active

PPBT

Biotechnology

Purple Biotech Ltd.

Quality

3.6

out of 10

Value Trap

—

Price

$2.81

Last close

Models

2/13

Active

Model-by-Model Comparison

Model	Type	PLX Fair Value	PLX Upside	PPBT Fair Value	PPBT Upside
Bayesian DCF	Intrinsic	$1.66	-20.9%	—	—
Earnings Power Value	Intrinsic	$3.20	+52.2%	—	—
EROIC Spread	Intrinsic	$2.54	+21.0%	$1.34	-52.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$3.90	+85.9%	$0.54	-80.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLX vs PPBT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLX vs PPBT — Which Stock Is More Undervalued?

PLX scores higher with a 7.6/10 quality rating vs PPBT's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protalix BioTherapeutics, Inc. (PLX) and Purple Biotech Ltd. (PPBT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLX currently trades at $2.10 with a QOC of 7.6/10, while PPBT trades at $2.81 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).